AI-assisted rare events screening
We are building HOPE METRIX®, a unique fourth-generation (GEN-IV) AI platform to empower researchers, startups, and the healthtech industry to advance their understanding of rare events through integrated multi-year risk modeling, uncertainties quantification, and early weak signals screening and characterization.
Before a rare event speaks, weak signals whisper
40%
of rare events in cancer or complex systems often emerge from preventable conditions linked to avoidable systemic risk factors.
40%
of rare events develop in complex systems or individuals whose increased risk potential could have been identified years earlier.
HOPE VALLEY AI® transforms complex, imbalanced, multimodal and multi-physics data into predictive weak signals, enabling integrated multi-year risk prediction through trustworthy fourth-generation AI solutions capable of early detection and characterization of rare events, years before they occur.
HOPE METRIX® is the GEN-IV AI platform, designed as a cross-domain technology to operate across multiple fields.
We are following Marie Curie’s legacy from a century ago by bringing nuclear innovation to the fight against cancer.
What is fourth-generation AI ?
Fourth-generation Artificial Intelligence (Gen-IV AI) refers to the aggregation of an ensemble of trustworthy risk-informed and multimodal AI algorithms, augmented with multi-physics methods, mathematics models, and risk engineering techniques such as imbalanced data and signals processing, uncertainties quantification and simulation, multi-year risk assessment and prediction, and safety-by-design control.
These advanced methods, models and systems are implemented to solve complex multi-scale problems with real-world integration and control optimization of operational constraints in compliance with regulatory references. It is inherently interdisciplinary, drawing on mathematics, computer science, engineering, and domain expertise.
We first focused on breast cancer and developed HOPE®, a smart breast health digital clinic, serving as a flagship demonstrator of our Gen-IV AI-assisted screening platform, with no clinical or diagnostic intent.
HOPE®, the first module of our smart modular breast health digital clinic, is a mobile application we launched in October 8, 2025, as a Class I CE-marked digital medical device, with registration number (01)03770040298008(8012)V1.0.6. HOPE® is available free of charge on App Store and Google Play. It is not a diagnostic tool and does not replace medical advice or a clinical examination by a healthcare professional. Please consult your doctor in case of doubt or unusual observation.
Securing innovation through IP
We currently own three (3) proprietary patents, all filed in early 2025, and hold exclusive rights for all healthcare applications to a portfolio of patented technologies licensed from CEA Paris-Saclay and Inria. This portfolio includes five (5) CEA patents (filed between 2013 and 2023), the SERENA medical dataset, and Inria’s AI software platform JULIA, the latter two being protected through APP deposits submitted by Inria to INPI France.
The core patented technology was developed by Dr. Hakima BERDOUZ, Founder & CEO of Hope Valley AI, through over 15 years of cutting-edge R&D in risk engineering and artificial intelligence at CEA Paris-Saclay and the Inria Start-up Studio in Paris.
We are committed to building a high-value, strategically aligned intellectual property portfolio, with a sustained goal of filing more than five (5) patent applications per year to secure and protect our technological innovations across fourth-generation AI, risk engineering and digital health.
Proud to be backed by
…and committed business angels, partners and sponsors.
